thyssenkrupp nucera (NCH2) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
12 Aug, 2026Executive summary
Delivered a solid quarter with strong performance in the chlor-alkali segment, robust project execution, and a healthy sales pipeline, including major new orders from China and successful projects in Brazil and the US.
Advanced green hydrogen projects with a major long-term service agreement in Spain, a strategic partnership with BHEL in India, and the Neom project nearing completion.
Regulatory and funding frameworks in the EU, India, and Japan are driving green hydrogen demand, supporting a substantial project pipeline and future growth.
Strategic decision to halt in-house SOEC stack production due to insufficient short-term market readiness, resulting in a one-time EBIT impact and future cost savings.
Order intake nearly doubled year-over-year in the first nine months, driven by strong growth in both green hydrogen and chlor-alkali segments.
Financial highlights
Q3 order intake reached EUR 81 million, up 29% year-on-year; nine-month order intake nearly doubled to EUR 471 million.
Q3 sales declined 21% year-on-year to EUR 145 million; green hydrogen sales fell to EUR 36 million, while chlor-alkali sales rose 34% to EUR 109 million.
Nine-month group sales declined 47% year-on-year to EUR 354 million, mainly due to maturing green hydrogen projects.
Q3 EBIT was stable at EUR -2 million; nine-month EBIT was EUR -69 million, impacted by EUR 50 million in one-time project costs.
Net financial assets stood at EUR 627 million at end of June 2026, reflecting a strong balance sheet.
Outlook and guidance
Updated FY order intake guidance to EUR 550–670 million, narrowing the previous range.
Group sales expected at EUR 450–500 million; EBIT forecast revised to EUR -105 to -75 million due to SOEC impairments.
Green hydrogen sales expected at EUR 100–130 million; EBIT for the segment at EUR -155 to -135 million.
Chlor-alkali sales guided at EUR 320–400 million, EBIT at EUR 45–65 million, with expectations to reach the midpoint.
Anticipates a new green hydrogen project award within calendar year 2026.
Latest events from thyssenkrupp nucera
- All agenda items passed as the company reported solid results and advanced its hydrogen strategy.NCH2
AGM 2026 - Industrial-scale electrolysis leader with strong growth, innovation, and ESG focus.NCH2
Investor presentation - Q2 order intake soared while sales and EBIT fell; outlook and liquidity remain robust.NCH2
Q2 2026 - Order intake guidance raised to €550–850m, but sales and EBIT guidance lowered for FY 2025/26.NCH2
Status update - Q1 sales and EBIT declined, but guidance and order momentum remain strong.NCH2
Q1 2026 - Record chlor-alkali sales and improved margins offset green hydrogen softness; outlook cautious.NCH2
Q4 2025 - Record sales and resilient AWE and CA growth drive strong performance amid market challenges.NCH2
Q4 2024 - Record sales and robust backlog, but AWE outlook clouded by regulatory and market delays.NCH2
Q3 2024 - Q2 sales up 31% YoY, EBIT and net income improved, FY guidance confirmed.NCH2
Q2 2025